Tourmaline Oil Corp. closed 7.6% below its 52-week high of C$70.83, which the company reached on February 21st.

Tourmaline Oil Corp. closed 6.2% below its 52-week high of C$70.83, which the company achieved on February 21st.

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total ...

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Tourmaline Bio (TRML – Research Report), with a price target of ...

After reviewing the many advantages of Xitox foot pads and considering the favorable reviews left by actual customers, we ...

My last article some years back noted that Charlie Lake had a lot of profit potential, and Tourmaline was there first. As the slide above shows, Charlie Lake has one of the best profit potentials ...

Fintel reports that on March 6, 2025, Wedbush initiated coverage of Tourmaline Bio (NasdaqGS:TRML) with a Outperform ...

Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...

NEW YORK - Tourmaline Bio, Inc. (NASDAQ: TRML) reported a wider fourth quarter loss on Wednesday, as the clinical-stage biotech company ramped up spending on research and development. Shares fell 2% ...

The retail merchandising company is leasing the top floor at Apex at Legacy, owned by Monarch Alternative Capital and ...